The dihydropyridine calcium channel antagonists, such as nifedipine, inhibit platelet aggregation in vitro and ex vivo, but the mechanism by which this occurs is uncertain. Bay K 8644 (BAY) is a substituted dihydropyridine that has effects on voltage-dependent calcium channels in cardiac and smooth muscle that are opposite the effects of nifedipine. To evaluate the mechanism responsible for dihydropyridine-induced inhibition of platelet function, we studied the in vitro effects of BAY on human platelet aggregation and secretion plus several related biochemical parameters, including cytoplasmic ionized calcium ( [Ca 2+ ],). BAY exerted concentration-dependent effects on platelet aggregation and secretion of [ I4 C] serotonin. BAY (1-10 |xm) inhibited the second wave of platelet aggregation and secretion stimulated by adenosine diphosphate or epinephrine and blocked shape change, aggregation, and secretion induced by the thromboxane A 2 (TXAJ mimic, U46619. BAY also inhibited 1146619-induced phosphorylation of the -40,000-dalton cytoplasmic protein substrate of protein kinase C (40K protein), formation of TXA 2 , and rise in [Ca 2+ ],, all biochemical consequences of platelet activation. The (+ )-(R) enantiomer of BAY [BAY( + )J was predominantly responsible for the inhibitory effects of racemic BAY. Nifedipine had the same inhibitory effects on platelet function and biochemistry, except it was ~ 10 times less potent than BAY. 1-10 nM BAY, BAY( +) and the ( -)-(S) enantiomer of BAY [BAY( -) ] all resulted in slight stimulation of platelet function and biochemical events. No significant increase in [ 3 H]U46619 binding was demonstrable, however. Therefore, dihydropyridines that function as either calcium channel agonists or antagonists in cardiac or smooth muscle exert concentration-dependent effects on platelet function. In nanomolar concentrations, they augment, and in micromolar concentrations, they inhibit platelet activation induced by TXA 2 or U46619. These data indicate that dihydropyridines do not inhibit TXA 2 -induced platelet activation by an effect on voltage-dependent calcium channels; they define the mechanism of inhibition as competitive antagonism of the TXA^-PGHj receptor. The mechanism responsible for augmentation of platelet activation is uncertain. The inhibitory effects of the antagonist dihydropyridines on platelet TXA^-PGH, receptors suggest that they may exert similar effects on vascular TXA,-PGH 2 receptors. (Circulation Research 1988;62:494-505) 
T he calcium channel blockers are a structurally heterogeneous group of drugs that share the common characteristic of inhibiting calcium entry into cells via voltage-dependent calcium channels. 1 -2 These drugs inhibit contractile events mediated by calcium influx in cardiac and smooth muscle cells. u>4 At higher concentrations ( > 1 \iM), the calcium channel blockers inhibit the function of other cells, such as blood platelets; however, platelets do not appear to have voltage-dependent calcium channels." Inhibition of platelet aggregation in vitro and ex vivo has resulted from exposure to nifedipine, verapamil, or diltiazem (for review, see Johnson et al 8 ) , representatives of the dihydropyridine, phenylalkylamine, and benzothiazepine classes, respectively, of calcium channel blockers. 9 The inhibitory effects of the calcium channel blockers have been observed in vitro at concentrations 10-100 times higher than those generally attained in vivo. 10 The mechanism by which calcium channel blockers inhibit platelet aggregation is only partially defined, and it appears to be multifactorial. It has been postulated that the calcium channel blockers inhibit platelet function by inhibiting calcium entry,' M5 but direct evidence in support of this postulate is limited and contradictory. 716 " 20 Inhibition of a 2adrenergic receptors, 58 -21 -22 or impaired formation of thromboxane A 2 (TXA,) 11 -12 -23 -25 or response to TXA 2 8 may also contribute to impairment of platelet aggregation by calcium channel blockers, but a unitary mechanism of action of these drugs on platelets has not been defined.
Recently, an interesting new class of pharmacological agents that have effects on voltage-dependent calcium channels opposite those of the calcium channel antagonists has become available. These so-called calcium channel agonists facilitate calcium entry into cells via voltage-dependent calcium channels. 26 One of the most widely studied of these agents is the substi-tuted dihydropyridine Bay K 8644 (BAY). 27 Although BAY functions primarily as a calcium channel agonist, it is actually a racemic mixture of two enantiomers that exert opposite effects on voltage-dependent calcium channels. To further define the mechanism responsible for calcium channel blocker-induced inhibition of platelet aggregation, the effects of BAY and BAY enantiomers on human platelet aggregation, secretion, and several closely linked biochemical events were evaluated.
Materials and Methods Subjects
Blood was obtained by antecubital venipuncture from healthy human volunteers who, during the preceding week, had taken no aspirin or other drugs known to inhibit platelet function. Each subject gave written informed consent in conformity with the provisions of a study approved by the Human Studies Subcommittee of the Minneapolis Veterans Administration Medical Center.
Materials
Carrier free H 3 
Platelet Preparation and Labeling Procedures
Human platelet-rich plasma (PRP) was obtained from freshly drawn sodium citrate (12.9 mM final concentration) anticoagulated blood by centrifugation at 200g for 15 minutes at room temperature. The platelets were then pelleted from the plasma by centrifugation at l,OOQg for 15 minutes at 4° C in the presence of 10 mM EDTA.
For studies of platelet aggregation, secretion, and phosphorylation, the platelets were resuspended in HEPES-citrate buffer (5 mM HEPES, 124 mM NaCl, 10.9 mM Na citrate-2H 2 O, 8.9 mM NaHCO 3 , 2.8 mM KC1, 0.1% dextrose, pH 7.4) at a density of 6 x 10 5 platelets/(j.l, divided into three fractions, and incubated at room temperature for 90 minutes with one of the following: -8 0 0 (iCi/ml [ 32 P]orthophosphate, -0 . 2 5 H-Ci/ml [ 14 C]serotonin, or HEPES-citrate buffer. The platelets were then collected by centrifugation at l,000g for 10 minutes at 4° C in the presence of 10 mM EDTA and resuspended in modified 30 Lindon's buffer 31 [-0.3 mM free ionized (Ca 2+ )] containing 2.5 mg/ml bovine serum albumin to a density of -3 X 1 0 5 platelets/|xl. Routinely, 10% of the 32 P radiolabel was found associated with the platelets, and 1% was incorporated into trichloroacetic acid-precipitable material. Greater than 90% of the [ 14 C]serotonin was taken up by the platelets.
For studies of [Ca 2+ ],, platelets were centrifuged at 15° C, and Rink's buffer 32 without calcium was used to resuspend the platelets to a density of 8 x 10 5 platelets/p,l. Fura-2 AM (1 mM) in dimethyl sulfoxide (DMSO) was added to a final concentration of 1 \LM, and the cells were incubated for 12 minutes at 37° C. The cells were washed by addition of four volumes of Rink's buffer, collected by centrifugation at 15° C in the presence of 10 mM EDTA, and resuspended in Rink's buffer to a density of 3 x 10 5 platelets/n-1. The external calcium concentration was adjusted to 1 mM free Ca 2+ just prior to study.
Receptor binding studies were performed on platelets derived from either sodium citrate-anticoagulated PRP (prepared as described above) or from 0.38% citrate-phosphate-dextrose-adenine (CPDAl)-anticoagulated PRP. The latter was prepared by collecting 450 ml blood in a standard blood donor collection bag and then separating the PRP by centrifugation at 1,746g for 3.5 minutes followed by 4,132g for 5 minutes at room temperature. An additional centrifugation at 200g for 15 minutes at 4° C was performed to remove contaminating red blood cells. Then the platelets were centrifuged in the presence of 10 mM EDTA and resuspended in HEPES-citrate buffer at a density of 2 x 10 6 platelets/jxl.
Platelet Aggregation
Platelet aggregation studies were performed in a dual-channel Payton aggregometer (Buffalo, New York). Platelets suspended in Lindon's buffer (0.45 ml) were placed in siliconized glass aggregometer cuvettes and warmed to 37° C for 3 minutes without stirring. The sample cuvettes were then placed in a 37° C-thermostated aggregometer and stirred, and 25 |xl plateletpoor plasma (fibrinogen source) was added. BAY, BAY enantiomer, nifedipine, or diluent buffer alone was added 1 minute prior to the addition of the appropriate aggregating agent (1% or 2% sample volume). Shape change was evaluated on the aggregometer tracings by observing a brief decrease in light transmission and narrowing of baseline oscillations immediately following the addition of the agonist. Aggregation was measured as the percentage of maximum change in light transmission obtainable against a buffer blank.
[ I4 C]Serotonin Secretion Time Course
Samples (0.45 ml) of [ 14 C]serotonin-labeled platelets were prepared for aggregation as described above, and 2 \iM imipramine was added. Platelets were stirred with the indicated agonist in a volume of 1% or 2% of the sample volume. Aliquots (100 ^1) were withdrawn at the indicated times and immediately mixed with 20 p.1 of 100 mM EDTA. The cells were then sedimented at 8,000g for 2 minutes, and duplicate 50-^,1 aliquots of the supernatant were mixed with Aquasol II (New England Nuclear) for liquid scintillation determination of the [ 14 C]serotonin released. Percentage [ 14 C]serotonin secretion was calculated from the counts per minute observed in the stimulated platelet supernatant (corrected for dilution) divided by the counts per minute in the whole platelet suspension (after blank subtraction) multiplied by 100.
Phosphorylation of 40K Protein
Samples (0.45 ml) of platelets were prepared as described above. After removing a 50-^.1 zero-time aliquot, the indicated agonist (in a volume of 1% or 2% of the sample volume) was added with continuous stirring. Aliquots (50 jxl) were withdrawn at the indicated times and immediately mixed with 25 p,l of a threefold concentrated denaturing sodium dodecyl sulfate-poryacrylamide gel electrophoresis (SDS-PAGE) sample buffer. The samples were heated at 100°C for 3 minutes. SDS-PAGE was performed on 12% poryacrylamide slab gels according to the procedure of Laemmli. 33 Aliquots (30 |xl) of the phosphorylation time-course samples, as well as molecular weight marker proteins, were applied to the gels, and they were electrophore$ed overnight at a constant amperage of 10 mA/plate. Protein bands were visualized with 0.5% Coomassie blue R. The 40K protein, which ran in the 45,000 molecular weight region of our gels, was excised from each lane, solubilized in hydrogen peroxide (70° C), and added to 10 ml Aquasol II; radioactivity was determined by liquid scintillation counting in a Packard TriCarb model 4640 counter (Downers Grove, Illinois). Phosphorylation of 40K protein disintegrations per minute was determined from the counts per minute obtained for each gel slice after background subtraction, through corrections for 32 P decay, platelet-specific activity, and platelet count. The data were standardized to 3 x 10 7 platelets with a specific activity of 727,500 dpm or 2,425 dpm/10 5 platelets.
Thromboxane B 2 Assay
Samples (0.45 ml) of unlabeled platelets were prepared for aggregation as described above. After initiation of aggregation, aliquots (100 \i\) were removed at the indicated times and mixed with 20 \i\ of 100 mM EDTA and 5 ^1 of 10 mM aspirin. The samples were cooled on ice for at least 20 minutes. The cells were sedimented at 8,00Qg for 2 minutes, and duplicate 50-jil aliquots were taken from the supernatant for thromboxane B 2 (TXB 2 ) analysis by radioimmunoassay. The concentration of TXB 2 was expressed as picograms per 3 x 10 7 platelets (100 \i\ platelet suspension). 2+ ], in the present study because it has several properties that make it a theoretically superior cell-permeant fluorescent probe, including 30 times greater fluorescence brightness than quin2, the commonly used indicator of [Ca^],, and less damping of intracellular calcium transients. 34 Because quin2 inhibits platelet function 35 and high concentrations of U46619 apparently have been required to stimulate a rise in platelet [Ca 2+ ] ; determined by quin2, 36 " 3 * fura-2 was chosen to maximize platelet function by minimizing calcium chelation. Platelet [Ca 2+ ], was determined as described by Grynkiewicz et al. 34 Samples (1.5 or 2.0 ml in a quartz cuvette) were placed in a Spex Fluorolog, and the basal levels of [Ca 2+ ]i were measured at room temperature without stirring using the spectral excitation ratio of 340 nm divided by 380 nm. The emission wavelength was 512 nm. The equation for calculating the molar concentration equivalent of these ratios is defined 34 as:
Fura-2 AM was chosen for determination of [Ca
The K^ for fura-2 calcium binding in the Rink's buffer system was observed to be 634 nM. This K^ is the mean value calculated from 340:380 excitation ratios observed with rysed fura-2-loaded platelets in standardized Ca-EGTA solutions. 34 For observation of agonistinduced change in [Ca 2+ ];, appropriate aliquots of an agonist (1% or 2% sample volume) were added to the cuvette, and the cuvette was inverted once. The scan was begun immediately with data points integrated for 2.5 seconds at 300, 340, and 380 nm repeatedly for 2 minutes. Peak [Ca 2+ ]j occurred within 15 seconds and decreased rapidly thereafter. The maximum [Ca 2+ ]j observed in each study was used for comparison with other studies. Most often, this was calculated from the ratio of 340 nM at 15 seconds to 380 nM at 17.5 seconds.
Platelet Binding of [ 3 H]Yohimbine
Platelet a 2 -adrenergic receptors were studied using [ 3 H]yohimbine by a method previously described 39 as modified in our laboratory. 8
Platelet Binding of pH]V46619
Binding of [ 3 H]U46619 to the TXA 2 -PGH 2 receptor was assayed by modification of methods previously described for study of human platelets. 40 -41 Aliquots of platelet suspension (1 ml containing 2 x 10 9 platelets) were incubated with [ 3 H]U46619 in combination with unlabeled U46619 (diluted in Tyrode's buffer) over a broad concentration range (5 nM-1.5 \LM) for 10 minutes at room temperature (~ 20° C) in a total volume of 1.9 ml. The binding reaction was terminated by the addition of 0.9 ml reaction mixture to 10 ml ice-cold HEPES-citrate buffer followed immediately by rapid filtration through Whatman GF/A glass fiber, filters (Maidstone, England) under reduced pressure. The filters were then washed with 15 ml ice-cold buffer. The entire filtration was complete in less than 15 seconds.
The radioactivity bound to the cells was determined by liquid scintillation counting in a Packard TriCarb model 4640 counter using 10 ml Aquasol II as the fluor. Platelet incubations (5-500 nM [ 3 H]U46619) to which a 1,000-fold molar excess of unlabeled U46619 was subsequently added were used to determine nondisplaceable binding. Nondisplaceable binding was routinely observed to be £20% of the total binding. Specific binding was defined as the difference between binding in the presence and in the absence of excess unlabeled ligand. Routinely, when inhibitors were included in the assay system, they were mixed with radioligand before platelet addition. On two occasions, platelets were preincubated with BAY for 5 minutes at room temperature before the radioligand was added and the assay was conducted. No additional effect of preincubation with BAY was observed.
Statistical Methods
Means, standard deviations, and correlation coefficients were calculated by standard methods. 42 Significance of differences between means was determined by Student's t test. 42 Equilibrium binding was analyzed by Scatchard plots. 43 Receptor inhibition was evaluated using Schild plots. 44 Antagonist dissociation constants (KJ were calculated using the Cheng-Prusoff relation. 45 Binding of [ 3 H]U46619 to platelets was analyzed using a computer program adapted from a nonlinear curvefitting program. 46 
Results

Platelet Aggregation and Secretion
The second wave of platelet aggregation induced by 5-10 \iM ADP or 0.5-5 ^M epinephrine was consistently inhibited by 1 u,M BAY and abolished by 1- (Figures 1 and 2) . This phenomenon was less consistently demonstrated than inhibition and appeared to require a precise threshold concentration of agonist to be manifested. The inhibitory effects of BAY on platelet aggregation suggested that BAY blocked the platelet response to TXA 2 . Stirring of platelets with BAY in the absence of platelet agonists did not result in aggregation or secretion. We previously demonstrated that the platelet aggregation response to TXA 2 or the stable endoperoxide and TXA 2 mimic, U46619, was blocked by the dihydropyridine calcium antagonist nifedipine. 8 Therefore, we evaluated the effect of BAY on U46619-induced f latelet responses. U46619-induced aggregation and l4 C]serotonin secretion were abolished by 1 JJLM BAY in a fashion similar to 10 \LM nifedipine. Data from a representative study are presented in Figure 3 . Shape To more thoroughly evaluate the inhibitory properties of BAY, the platelet aggregation response was titrated with varying concentrations of U46619 in the absence or presence of several concentrations of BAY. The results of these experiments are presented in Figure  4 . The ECJO value observed for U46619 was 43 nM, and this value increased to 1,095 nM in the presence of 10 p,M BAY. Reorganization of this data into the form of a Schild plot 44 ( Figure 4B ) produced a straight line with a slope of -1.1 and anx-intercept (-log K b ) equal to 692 nM. These data suggested that BAY was a competitive antagonist of U46619 binding with a binding constant of -7 0 0 nM. The EQ,, for U46619-induced [ 14 C]serotonin secretion was approximately two times greater (93 nM) than the ECj,, for aggregation.
The results of these studies indicated that inhibition of platelet aggregation and secretion by dihydropyridines was mediated by interference with TXA 2 -PGH 2 receptor-mediated events. Since binding of agonists to platelet receptors triggers several immediate biochemical responses, including phosphorylation of 40K protein, rise in [Ca 2+ ],, and liberation of arachidonic acid that is converted to TXA 2 , the effect of BAY, BAY isomers, or nifedipine on these parameters was observed.
40K Protein Phosphorylation
Phosphorylation of 40K protein induced by threshold concentrations of U46619 was inhibited by 1 p-M BAY or 10 |xM nifedipine. Data from representative individual studies are presented in Figures 5 and 6 . The degree of inhibition of phosphorylation observed was inversely proportional to the concentration of U46619 used to stimulate the platelets ( Figure 5 versus Figure 6 ). The TXA 2 -PGH 2 receptor antagonist, 13-azaprostanoic acid/ 7 inhibited platelet aggregation and secretion and 40K protein phosphorylation in a fashion nearly identical to that of BAY ( Figure 7) .
The expectation that fura-2 would not significantly inhibit platelet function and thereby allow evaluation of the rise in [Ca 2+ ], stimulated by threshold concentrations of U46619 was fulfilled. Fura-2-loaded platelets usually aggregated fully in response to 0.057-0.095 JJLM U46619 rather than 1 LIM U46619 used in most quin2 studies. 36 Rink's buffer with 1 mM Ca 2+ was equal to that of control non-fura-2-labeled platelets.
In buffer containing 1 mM Ca, basal [Ca 2+ ]; was 135 ± 2 3 nM (mean±SD; n = l5). In calcium-free buffer, basal [Ca 2^ was 33 ± 12 nM. The rise in [Ca 2+ ]i stimulated by U46619 (0.057-0.095 JJLM) in the presence of 1 mM Ca was 192 ± 4 9 nM (n = 15) over basal. Concentration-dependent increments in [Ca 2+ ], were observed between 0.01 and 0.1 JJLM U46619, but higher concentrations did not further increase [Ca 2+ ]|. Thrombin (0.2 U) increased [Ca 2+ ], 801.9±151 nM (n -8) over basal values in the presence of 1 mM Ca 2+ . In the absence of external calcium, the rise in [Ca 2+ ], stimulated by U46619 was 115 ± 2 0 nM over basal (n = 4). When 1 mM EGTA was added, the rise in [Ca 2 *], was further reduced to 60 nM over basal.
BAY (1 M-M) had no effect on basal [Ca 2+ ] i5 and it failed to inhibit the immediate rise in [Ca 2+ ]j that followed the addition of 1 mM Ca to platelets in calcium-free buffer. However, in the presence of 1 mM Ca, the rise in [Ca 2+ ]j stimulated by U46619 was significantly inhibited by 1 u,M BAY, exhibiting a mean decrease of 67 ±8.4% (n = 6) (p<0.01), and was completely inhibited (98.5%) by 10 \iM BAY. In the absence of external calcium with or without EGTA, the rise in [Ca 2+ ], stimulated by U46619 was completely blocked by 1 fiM BAY. The rise in [Ca 2+ ]j stimulated by U46619 in the presence of 1 mM external Ca was slightly and consistently increased by 1-10 nM BAY (mean increase 13.0±6.9%, n = 6; p<0.05) when platelet aggregation and/or secretion was stimulated. Similar stimulation was observed with < 1 |xM nifedipine; however, comparable inhibition of the rise in [Ca 2+ ]j was achieved only at 20 JJLM nifedipine.
To further understand the antagonist and agonist properties of BAY, the BAY enantiomers, BAY( + ) and BAY( -) , were examined individually. BAY( + ) and BAY( -) were found to have different effects on aggregation, secretion, and [Ca 2+ ],. BAY( + ) (1 p,M), like BAY, markedly inhibited platelet aggregation (K,~110 nM) and secretion and the rise in [Ca 2+ ]; stimulated by U46619 (Table 1 ). In contrast, BAY( -) had much less of an inhibitory effect on U46619induced aggregation (K,~3 \iM), secretion, and elevation of [Ca 2+ ]|. The composite results of the effects of BAY( -) and BAY( + ) ( Table 1 ) conform closely to those that would be predicted from a racemic mixture of BAY when the inhibitory function is primarily dependent on one enantiomer [BAY( + ) ] . At 1-10 nM, both enantiomers potentiated platelet aggregation and secretion similar to the results obtained with BAY, and at 1 nM, they both slightly increased the rise in [Ca 2+ ], stimulated by U46619 (Table 1) .
Thromboxane B 2 Formation
TXB 2 formation stimulated by 0.072-0.095 \iM U46619 was 742 ±504 pg/3xlO 7 platelets (n = 24) and 508 ±220 pg/3xlO 7 platelets for 0.057 \iU U46619 (n = 7). TXB 2 formation stimulated by U46619 was substantially and consistently inhibited by 1 JJLM BAY and BAY( + ), but B A Y ( -) was not inhibitory. Data from a representative study are presented in Table 2 . BAY (1-10 jxM) decreased TXB 2 formation by 185-433 p g / 3 x l 0 7 platelets (n = 6) compared with concurrent control determinations. Conversely, 1 nM BAY, BAY( + ), and B A Y ( -) all augmented U46619-induced TXB 2 formation ( Table  2 ). BAY (1-10 nM) consistently increased TXB 2 formation by 51-469 pg/3 x 10 7 platelets (n = 8) compared with concurrent control values.
Receptor Binding of [ 3 H]U46619 and [ 3 H]Yohimbine
Since each of the receptor-linked biochemical parameters was markedly inhibited by > 1 \iM BAY, the effect of BAY, BAY enantiomers, and nifedipine on binding of [ 3 H]U46619 to platelet TXA 2 -PGH 2 receptors was evaluated. The binding of [ 3 H]U46619 was observed between 0.005 and 1.5 \iM. Scatchard analysis revealed a nonlinear plot (Figure 8 ) indicative of either multiple binding sites or negative cooperativity between sites. The results represent specific binding because nondisplaceable binding values were subtracted from the total binding data before calculations were done. Computer analysis of the data indicated that the best fit was obtained with a two-site model that identified one high-affinity binding site with a K, of 131 ± 5 8 nM (n = 6) and a B^ of 177±53 fmol/10 8 platelets (1,067 ±322 binding sites/platelet) and one low-affinity binding site with a K^ of 1.71 ±0.74 p,M (n = 6) and 3,740 ±1,400 binding sites/platelet. The previous aggregation studies revealed an EC,,, value of 43 nM for U46619; therefore, the effect of BAY over the substrate concentration range where biological activity was demonstrated (10-200 nM) was observed. The inhibitory effects of BAY on U46619 binding are shown in Figure 9 and Table 3 . A . . . 539+103 518+137 780±70 •Increase in thromboxane B 2 between 5 seconds and 3 minutes after addition of 0.057 fiM U46619 (mean + SD for six replicate determinations). dose-dependent relation was observed (Figure 9 ). The mean K, for BAY calculated from data obtained in four studies using five concentrations of (Table 3) . BAY(-) inhibited [ 3 H]U46619 binding minimally at 10 JJLM (<20% inhibition at the lowest U46619 concentration). BAY( + ) was more inhibitory than racemic BAY with a Kj of 230 nM. For comparative analysis, the K^ for the potent TXA 2 -PGH 2 receptor antagonist SQ 29,548' t0 was evaluated and found to bẽ 5 nM. A similar study with nifedipine as the antagonist produced a Kj of 38 jiM.
Binding studies were conducted at nanomolar concentrations of BAY to observe increased binding of [ 3 H]U46619. The binding data for BAY and the BAY enantiomers averaged 97.5 ± 4% of the control value, with no consistent increase observed.
Finally, to establish that the BAY effects were TXA 2 -PGH 2 receptor-specific, the binding of radiolabeled yohimbine to platelet ct 2 -adrenergic receptors in the presence or absence of 10 n,M BAY was examined. No difference in the a 2 -adrenergic receptor binding constant or receptor number per platelet was observed in the presence of BAY (control: K^ 2.16 ±0.76 nM, 222 ± 73 sites, n = 5; 10 u,M BAY: K, 1.69 ± 0.61 nM, 194 ±51 sites, n = 5).
Discussion
BAY is a substituted dihydropyridine that is classified as a calcium channel agonist on the basis of its predominant effect on vascular and cardiac muscle. 3 -26 BAY stimulates calcium influx via voltage-dependent calcium channels in cardiac and smooth muscle by increasing the probability that calcium channels will be in the open gating mode. 48 This results in positive inotropy in the intact heart and vasoconstriction of arterial smooth muscle. 2 *-4950 However, in the isolated perfused heart 49 and mesenteric artery, 50 BAY between 1 nM and 1 ^,M exerts agonistic effects and above 1 (xM exerts antagonistic effects. 49 This concentrationdependent change in function may be attributable to the fact that BAY is a racemic mixture of optical isomers that have different binding affinities for dihydropyridine receptors 51 and opposite functional effects on calcium channels. 47 -51 The (-)-(4S) enantiomer [BAY( -) ] possesses the predominant calcium agonistic properties of the racemic compound, 52 while the ( + )-(4i?) enantiomer [BAY( + )] has calcium channel-antagonistic properties similar to those of nifedipine. 52 Similar agonistic and antagonistic properties of the S and R enantiomers of another substituted dihydropyridine, 202-791, have also been reported. 53 Although the concentration-dependent stimulatory and inhibitory effects of BAY on platelet function suggested that platelets have voltage-dependent calcium channels, critical differences existed between the effects of BAY and its enantiomers on platelets and on cardiac and smooth muscle. In these tissues, the predominant effect of BAY over a broad concentration range was previously found to be that of an agonist, 49 while in the platelet, BAY in the same concentration range was found to be predominantly an antagonist. Although this antagonism, as in vascular tissues, was primarily attributable to BAY( + ), the agonist effects of BAY( -) were found to be weakly manifested in the platelet. Also, in sharp contrast to its effect on cardiac and smooth muscle, the effect of BAY on platelets was identical to that of the calcium channel blocker, nifedipine, except that it was 10-20 times more potent an inhibitor. Therefore, our observations supported the conclusions of others that platelets do not possess voltage-dependent calcium channels. 20 -54 " 56 As a consequence, we pursued an alternative hypothesis, namely, that dihydropyridines modulate receptormediated platelet activation.
In the present study, BAY and BAY( + ), like nifedipine, inhibited platelet shape change and aggregation in a concentration-dependent fashion. A Schild plot of the effect of BAY on U46619-induced platelet aggregation indicated competitive antagonism of the TXA 2 -PGH 2 receptor. We also found that BAY, BAY( +), and nifedipine inhibited platelet secretion m "a a. mediated by ADP, epinephrine, sodium arachidonate, and low concentrations of collagen. Because platelet secretion by these agonists is dependent on TXA 2 and because 40K protein phosphorylation, TXA 2 formation, and a rise in [Ca 2 *]; are biochemical events that accompany secretion, 36 -55 " 58 it is significant that increases in all of these parameters stimulated by threshold concentrations of U46619 were inhibited by > 1 JJLM BAY or BAY( + ) and by a 10 p,M nifedipine.
These results were compatible with the hypothesis that the dihydropyridines inhibited the platelet TXA 2 -PGH 2 receptor. Precedent for this mechanism was provided by the earlier observation that release of intracellular calcium by TXA 2 was blocked by the TXA 2 -PGH 2 receptor antagonist, 13-azaprostanoic acid. 59 -60 In the present study, 13-azaprostanoic acid blocked aggregation, secretion, and 40K protein phosphorylation in the same manner as BAY. In addition, the platelet-receptor for platelet activating factor has been shown to be inhibited by dihydropyridines. 61 Since our data strongly implicated receptor inhibition as the mechanism responsible for dihydropyridineinduced impairment of TXA 2 -induced platelet activation, the effect of BAY, B A Y ( -) , BAY( + ), and nifedipine on binding of [ 3 H]U46619 was measured. Scatchard analysis of our binding data produced a high-affinity binding constant of 131 nM, similar to that reported by Kattelman et al 40 of 108 nM. The lowaffinity site observed is perhaps the result of activation on binding of the agonist causing secondary site appearance. Although the binding profile may have been altered by receptor activation, these results cannot be attributed to platelet aggregation and secretion because these platelets were suspended in cationdeficient buffer. The effects of BAY and the BAY enantiomers, given in Table 3 , were analyzed using the high-affinity K^ of 131 nM. This study confirmed our suspicion that inhibition of U46619-induced platelet activation by BAY, BAY( + ), and nifedipine was attributable to competitive receptor binding. BAY was a less-potent inhibitor than the specific TXA 2 -PGH 2 receptor antagonist, SQ 29,548, but it was comparable to that of other antagonists, 13-azaprostanoic acid or BM13.177. 40 The Kifor BAY inhibition of [ 3 H]U46619 receptor binding (1.47 p.M) was higher than the Kj for BAY inhibition of platelet aggregation ( -0 . 7 \iM). Since the EG*, for U46619-induced platelet release of [ 14 C]serotonin was approximately twice the EQo for platelet aggregation, it appears that secretion is more closely related to the extent of receptor occupancy than is aggregation. Apparently, maximal aggregation can be elicited by only partial TXA 2 -PGH 2 receptor occupancy. Since 10 ^M BAY, like 10 u-M nifedipuie, 8 had no effect on [ 3 H]yohimbine binding to platelet a 2adrenergic receptors, dihydropyridine inhibition of the TXA 2 -PGH 2 receptor was not due to a generalized effect on membrane receptors.
The inhibitory effects of BAY were attributable primarily to the BAY( + ) ehantiomer. Confirmation of the fact that the R enantiomer configuration was responsible for the inhibitory effect was obtained from studies recently performed with enantiomers of the substituted dihydropyridine, 202-791, kindly supplied by Drs. A. Lindemann and H. Stahelin, Sandoz LTD, Basal, Switzerland. The R and S enantiomers of 202-791 were synthesized separately and thus were chemically pure. 53 Previous studies demonstrated that the R enantiomer had only inhibitory effects on rabbit aorta, while the S enantiomer was a pure stimulator of contraction and [ 45 Ca 2+ ] uptake. 53 We found that the R enantiomer of 202-791 also inhibited U46619-induced platelet aggregation, secretion, and [ 3 H]U46619 binding. However, it was approximately 10-fold less potent than BAY( + ) , the R enantiomer of BAY. At 10 M-M, the S enantiomer of 202-791 had no inhibitory effect on [ 3 H]U46619 binding to platelets and only minimal 
4.76
Data is taken from one representative study.
•Calculated with a Kj = 120 nM (Bay K 8644 concentrations studied = 0.49, 1.0, 4.9, and 10 M) inhibitory effects (<20%) on platelet aggregation and secretion.
The stimulatory effect of nifedipine, BAY, and its enantiomers observed at low concentrations is more difficult to explain. At 1-10 nM, each of the dihydropyridines appeared to facilitate all of the biochemical parameters linked to receptor activation. It is possible that these drugs facilitated TXA 2 -PGH 2 receptor binding; however, an increase in [ 3 H]U46619 binding to platelets in the 1-10 nM concentration range could be demonstrated. It is also possible that they potentiated platelet aggregation and secretion by stimulating calcium influx, possibly via a vestigial population of voltage-dependent calcium channels or the receptoroperated calcium channels considered to exist in smooth muscle 62 -63 and postulated to be operative in platelets. 54 However, the complex relations that exist among external platelet binding sites for calcium, intracellular storage pools, and calcium influx 64 " 67 and the lack of convincing documentation of the existence of either type of calcium channels in platelets permit only speculation regarding such mechanisms.
The observations made in the present study cannot be directly transferred to other cells; however, they may have implications for interpreting the effects of dihydropyridines on cardiac and vascular smooth muscle. It is possible that an effect of these drugs on receptormediated calcium flux, in addition to their betterknown effects on voltage-dependent calcium channels, could explain some of the difficulties encountered in constructing an adequate model to explain their mechanism of action. 3 -4 -26 ' 68 ' 69 Because TXA 2 is a potent vasoconstrictor and blood vessels have TXA 2 -PGH 2 receptors, 70 it is also possible that the dihydropyridines inhibit TXA 2 -induced vasoconstriction in part by competitive inhibition of vascular TXA 2 -PGH 2 receptors. Future studies of the effect of dihydropyridines on receptor function may help to clarify the mechanism of action of these drugs.
